We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
Oncology
We pioneer treatments in cancer, advancing bold science
Where we plan to expand
- Focus: solid tumors & hematology
- Precision medicine approaches
- Assets of interest:
- Best- or first-in-class assets with strongscience and meaningful differentiation
- Biomarker segments
- Market focus: Smaller patient segmentsattractive for mid-sized companies
Rare Disease
We pioneer treatments in cancer, advancing bold science
Where we plan to expand
- Focus: High unmet needs in underservedrare diseases
- Assets of interest: Drive liver & bonefranchises; expand to new disease areas
- Market focus: Pursuing assets with a good fitfor clinical development and go-to-marketmodel
Neuroscience
At Ipsen, we are pushing the boundaries of science to deliver neurotoxin
Where we plan to expand
- Focus: Rare neurological disorders in pre-proof-of-concept programs; exploring rareand non-rare disorders in Phase III andbeyond
- Assets of interest: Expand beyondneurotoxins in non-rare to adjacent areas
- Market focus: Strong innovation andscientific advances
Contact the partnering team
At Ipsen, partnering is personal and purpose-led. Our team is committedto success and has the expertise to deliver it. Contact us to see howtogether, we can accelerate innovation for patients.
Pipeline
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
Learn morePartnering announcements
02 March 2023
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
09 January 2023
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver…
12 August 2022
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
27 June 2022
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Investigator Sponsored Studies and Externally Sponsored Coll
We are ready to consider supporting Investigator Sponsored Studies and Externally Sponsored Collaboration because we recognize that this research can play a key role in answering important medical and scientific questions regarding our products and/or their related therapeutic areas. Any support request must be submitted via our dedicated portal.
